EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Prochlorperazine maleate versus placebo for the prophylaxis of acute mountain sickness: a double-blind randomized controlled trial

Elan Small, Harrison Steins, Martin Musi, Julia Perry, Elizabeth Goldberg, Mary Ryan, Lake Crawford, Brian Strickland, Tiana Linkus, Caleb Phillips, Ryan Paterson, Nathaniel Zona und 8 weitere

Journal of Travel Medicine · 01.07.2025 · 32 (5)

DOI: 10.1093/jtm/taaf044 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Travel Medicine, online erschienen am 22.05.2025. Verfasst von Elan Small und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Section of Wilderness & Environmental Medicine, University of Colorado School of Medicine, 12401 E 17th Avenue, Aur…. Hauptthemen laut MEDLINE: Altitude Sickness, Prochlorperazine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, GeoSentinal Foundation, International Society of Travel Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute mountain sickness (AMS) is a debilitating condition that may occur on ascent to high altitude, with limited options for chemoprophylaxis. The pathophysiology of AMS is poorly understood, though it may be similar to migraine. This study aimed to determine the efficacy of prochlorperazine, a first-line agent for acute migraine, for AMS prophylaxis.

Methods

We performed a randomized, double-blind, placebo-controlled trial involving healthy, unacclimatized adult participants, primarily from the Denver area (1609 m), who received either oral prochlorperazine or placebo three times daily for 24 hours during rapid ascent to Mount Blue Sky, Colorado (4348 m). We evaluated individuals who received at least the first dose of placebo or intervention following a modified intent-to-treat approach. Participants travelled by vehicle to 3910 m, then hiked to the summit of Mount Blue Sky, where they slept overnight. The primary outcome was AMS incidence as defined by the 2018 Lake Louise Questionnaire, which was assessed on the evening of ascent and the following morning.

Results

We analysed 56 participants (25 women), with a mean age of 39 [IQR 28–49], with 28 participants in each study arm. Key baseline characteristics were equally distributed and well-matched between study arms. The incidence of AMS was 28 (50%), with 18 (64%) in the placebo arm and 10 (36%) in the prochlorperazine arm (P = 0.06). The absolute risk reduction was 28.6%, the number needed to treat was 4 and the odds ratio was 0.28 (95% C.I. 0.11–0.94). There were no serious adverse events, and there were no significant differences in the side effects between arms, including for drowsiness (P = 0.47).

Conclusion

Our results suggest that prochlorperazine is effective in preventing AMS. Larger studies are warranted to validate our findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Altitude SicknessProchlorperazineHumansDouble-Blind MethodMaleFemaleAdultMiddle AgedColoradoAcute DiseaseTreatment OutcomeMountaineering

Stichwörter der Autor:innen

Acute mountain sicknessclinical trialhigh altitude illnessprevention

Substanzen

Prochlorperazine

Autor:innen und Institutionen

  • Department of Emergency Medicine, Section of Wilderness & Environmental Medicine, University of Colorado School of Medicine, 12401 E 17th Avenue, Aurora, CO, 80045, USA.
  • Rocky Vista University, College of Osteopathic Medicine, 8401 South Chambers Road, Englewood, CO, 80112, USA.
  • Department of Computer Science, University of Colorado Boulder, 1111 Engineering Drive, Boulder, CO 80309, USA.
  • Department of Orthopedics, University of Colorado School of Medicine, 12631 East 17th Avenue, Aurora, CO, 80045, USA.
  • Department of Physics & Astronomy, University of Denver, 2112 East Wesley Avenue, Denver, CO, 80208, USA.
  • Department of Geography & the Environment, University of Denver, 2050 East Iliff Avenue, Denver, CO, 80208, USA.

Förderung

  • NIA NIH HHS
  • GeoSentinal Foundation
  • International Society of Travel Medicine
  • NIH

Zitieren

APA

Small, E., Steins, H., Musi, M., Perry, J., Goldberg, E., Ryan, M., Crawford, L., Strickland, B., Linkus, T., Phillips, C., Paterson, R., Zona, N., Smolkin, M., Derstine, M., Lemery, J., Hoffman, J. L., Hick, S. R., Ginde, A. A., Hackett, P., & Keyes, L. E. (2025). Prochlorperazine maleate versus placebo for the prophylaxis of acute mountain sickness: a double-blind randomized controlled trial. Journal of Travel Medicine, 32(5). https://doi.org/10.1093/jtm/taaf044

Vancouver

Small E, Steins H, Musi M, Perry J, Goldberg E, Ryan M, et al. Prochlorperazine maleate versus placebo for the prophylaxis of acute mountain sickness: a double-blind randomized controlled trial. Journal of Travel Medicine. 2025;32(5). doi:10.1093/jtm/taaf044

BibTeX
@article{Small2025,
  author = {Small, Elan and Steins, Harrison and Musi, Martin and Perry, Julia and Goldberg, Elizabeth and Ryan, Mary and Crawford, Lake and Strickland, Brian and Linkus, Tiana and Phillips, Caleb and Paterson, Ryan and Zona, Nathaniel and Smolkin, Max and Derstine, Mia and Lemery, Jay and Hoffman, Jennifer L and Hick, Steven R and Ginde, Adit A and Hackett, Peter and Keyes, Linda E},
  title = {Prochlorperazine maleate versus placebo for the prophylaxis of acute mountain sickness: a double-blind randomized controlled trial},
  journal = {Journal of Travel Medicine},
  year = {2025},
  volume = {32},
  number = {5},
  doi = {10.1093/jtm/taaf044}
}
Kostenlos starten →